New drug combo aims to clear hepatitis c virus for good
NCT ID NCT01753570
First seen Jan 08, 2026 · Last updated May 11, 2026 · Updated 21 times
Summary
This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). The goal was to see if the combination could make the virus undetectable in the blood 24 weeks after treatment ended, known as a sustained viral response. Participants were either new to treatment or had tried interferon-based therapy before. The study is complete, and results help understand how well this triple therapy works for controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C(CHC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, 213-8587, Japan
Conditions
Explore the condition pages connected to this study.